Objective To analyze the clinical effect of tiotropium bromide powder for inhalation and low flow oxygen inhalation in the treatment of stable chronic obstructive pulmonary disease (COPD) combined with chronic respiratory failure. Methods A total of 82 stable chronic obstructive pulmonary disease combined with chronic respiratory failure patients were divided by random number table into observation group (44 cases) and control group (38 cases). The control group received low flow oxygen inhalation, and observation group also received tiotropium bromide powder for inhalation. Clinical effect was compared between two groups after 3-month treatment. Results Both groups had higher forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) after treatment than before treatment, and differences had statistical significance (P<0.05).Before treatment, the control group had COPD self-assessment test (CAT) score as (30.6±3.1) points and (29.9±3.6) points in observation group, there was no statistical significance differences in two groups (P>0.05). After treatment, the control group had CAT score as (26.5±3.1) points and (23.7±2.2) in observation group. Both groups had lower CAT score after treatment than before treatment, and observation group had a lower CAT score than control group, all the differences had statistical significance (P<0.05). After treatment, both group had higher arterial partial pressure of oxygen (PaO2) than before, and observation group had lower arterial partial pressure of carbon dioxide (PaCO2) than control group, all the differences had statistical significance (P<0.05). The control group had no significant difference in PaCO2 than before (P>0.05). The observation group had higher PaO2 than control group and lower PaCO2 than control group, and differences had statistical significance (P<0.05). Conclusion Tiotropium bromide powder for inhalation and low flow oxygen inhalation can effectively perfect lung function and blood gas analysis index of stable chronic obstructive pulmonary disease combined with chronic respiratory failure patients. This method also can improve quality of life and has significance application value.%目的：分析噻托溴铵吸入剂联合低流量吸氧治疗稳定期慢性阻塞性肺疾病(慢阻肺)合并慢性呼吸衰竭患者疗效。方法82例稳定期慢阻肺合并慢性呼吸衰竭患者，按照随机数字表法分为观察组(44例)和对照组(38例)。对照组行低流量吸氧治疗，观察组在对照组基础上联合噻托溴铵吸入剂治疗，治疗3个月后比较两组患者的临床效果。结果治疗后，两组用力肺活量(FVC)及第一秒钟用力呼吸容积(FEV1)指标均高于治疗前，且观察组指标高于对照组，差异有统计学意义(P<0.05)。治疗前，对照组慢阻肺自我评估测试(CAT)评分为(30.6±3.1)分，观察组为(29.9±3.6)分，比较差异无统计学意义(P>0.05)；治疗后，对照组 CAT 评分为(26.5±3.1)分，观察组为(23.7±2.2)分，治疗后两组 CAT 评分均低于治疗前，且观察组的CAT评分低于对照组，差异有统计学意义(P<0.05)。治疗后，两组氧分压(PaO2)均高于治疗前，观察组二氧化碳分压(PaCO2)低于治疗前，差异有统计学意义(P<0.05)，但对照组 PaCO2与治疗前比较差异无统计学意义(P>0.05)，观察组 PaO2高于对照组， PaCO2低于对照组，差异有统计学意义(P<0.05)。结论噻托溴铵吸入剂联合低流量吸氧治疗稳定期慢阻肺合并慢性呼吸衰竭可有效改善患者的肺功能、血气分析指标，提高了患者的生活质量，具有重要的应用价值。
展开▼
